In six families with hereditary neuropathy with liability to pressure palsies (HNPP) the 17p11.2 deletion was absent, but single strand conformation-analysis and subsequent sequencing demonstrated a heterozygous Ginsertion in a stretch of six Gs at nt 276-281 of the PMP22 gene, resulting in a frame shift after Gly94. Haplotype comparison of the six families revealed common ancestry. We compared the phenotype of 23 patients from these six families with the phenotype of 63 patients of 17 families with the common deletion. The patients with the G-insertion showed the clinical, electrophysiological and morphological characteristics Keywords: hereditary neuropathy with liability to pressure palsies; peripheral myelin protein 22; chromosome 17p11.2 deletion; hereditary motor and sensory neuropathy; Charcot-Marie-Tooth disease Abbreviations: CMT ϭ Charcot-Marie-Tooth disease; HMSN ϭ hereditary motor and sensory neuropathy; HNPP ϭ hereditary neuropathy with liability to pressure palsies; PMP22 ϭ peripheral myelin protein 22
Introduction
Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant disorder characterized by recurrent sensory or motor dysfunction, often precipitated by minor trauma (De Jong, 1947; Behse et al., 1972; Madrid and Bradley, 1975; Verhagen et al., 1993) . Few patients present with a progressive symmetrical motor and sensory neuropathy (Verhagen et al., 1993) . Electrophysiological studies demonstrate an underlying generalized neuropathy with moderate slowing of conduction velocities, predominant slowing over nerve entrapment sites and prolonged distal latencies (Behse et al., 1972; Verhagen et al., 1993) . These abnormalities are also present in some clinically
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of common HNPP, but in addition they had significantly more neuropathic features, mimicking hereditary motor and sensory neuropathy type I (HMSN I) or CharcotMarie-Tooth disease type 1 (CMT1). To explain this distinct phenotype we suggest that, by translation of the mutated gene, a markedly changed polypeptide is formed without the normal cytoplasmic C-terminal of the native protein, resulting in a loss of function similar to that with the common deletion, but exerting an extra disturbance of Schwann cell functions, probably by hampering normal myelin formation or maintenance.
asymptomatic relatives. Nerve biopsy specimens show focal myelin thickenings (tomacula) and a variable degree of segmental demyelination and axonal loss (Behse et al., 1972; Madrid and Bradley, 1975; Verhagen et al., 1993) . The genetic defect in most HNPP families is a 1.5-Mb deletion on chromosome 17p11.2, which is duplicated in hereditary motor and sensory neuropathy (HMSN) type Ia or CharcotMarie-Tooth (CMT) 1A and encompasses the gene for the peripheral myelin protein PMP22 (Chance et al., 1993) . In a minority of HNPP families no 17p11.2 deletion is detected (Mariman et al., 1994; Harding, 1995) . Three HNPP families showed a frame shift mutation in the PMP22 gene; one patient had a nonsense mutation and one family carried a point mutation at the 5Ј donor splice site of the first intron of the PMP22 gene, 78ϩ1(G→T), all supporting the pathogenic role of the resulting abnormal PMP22-gene expression in producing the HNPP phenotype (Nicholson et al., 1994; Taroni et al., 1995; Pareyson and Taroni, 1996; Bort et al., 1997; Young et al., 1997) .
We found the same frame shift mutation as described by Young et al. (1997) in 23 patients from six non-deletion HNPP families. We compared the phenotype of these patients with the phenotype of 63 patients of 17 families with the common 17p11.2 deletion and found a different phenotype. One patient with this mutation has been described before as an atypical case of HNPP (case 3 in Gabreëls-Festen et al., 1992) .
Patients and methods
We investigated 86 patients from 23 families with HNPP after informed consent was given. The study was approved by the ethics committee of the University Hospital Nijmegen. A detailed clinical history was obtained, especially for symptoms of a chronic distal motor and sensory neuropathy and transient palsies or sensory dysfunction. All patients underwent standardized neurological examination.
Electrophysiological investigations included motor nerve conduction velocities of ulnar and peroneal nerves below and across pressure sites (elbow and fibular head, respectively), distal motor latencies of ulnar and peroneal nerves, and sensory nerve conduction of the median and sural nerves (Verhagen et al., 1993) .
Morphology
Diagnosis had been confirmed previously in the index patient of each family by sural nerve biopsy. Nerves were prepared for light and electron microscopical investigation, including teased fibre studies, using standard techniques (Vos et al., 1983) . The total transverse fascicular area was assessed with the aid of a planimeter on photographic enlargements of semithin sections of the nerve. Electron microscopic photographs (ϫ1700) covering~10% of the total transverse fascicular area were used for morphometrical analysis. The density and diameter distribution of myelinated axons were determined using a Zeiss TGZ 3 particle size analyser. On the same prints the number of onion bulbs were scored in randomly chosen areas covering 100 myelinated fibres. All concentric structures composed of at least two extra Schwann cell processes were considered to be onion bulbs. The frequency of fibres with tomacula was counted in 30-100 teased fibres from each biopsy. The diameters of tomacula were represented by the mean diameter of the 10 largest tomacula, as observed in two longitudinal cryostat sections.
Molecular analysis
For genetic analysis the following microsatellite markers were used: D17S936, D17S922, D17S921, D17S955, D17S839, D17S122, D17S261, D17S953, D17S740 and D17S925. All markers were analysed by PCR (polymerase chain reaction) amplification of 50 ng genomic DNA using the markerspecific primers (Genome Database; Isogen Bioscience, The Netherlands) under the conditions described before (Mariman et al., 1994) . After amplification, allelic bands were separated by electrophoresis on 6.6% denaturing polyacrylamide gels. Subsequently, gels were dried and exposed overnight to Kodak X-omat S film to visualize the allelic bands. Linkage analysis was performed using the Mlink routine of the LINKAGE program (version 5.1) assuming complete penetrance and a disease gene frequency of 0.0001. Allele frequencies for each marker were determined by genotyping 40 unrelated persons randomly selected from the Dutch population. For mutation detection and sequencing, the different exons of the PMP22 gene were amplified from the DNA of patients and various unrelated controls using the previously reported primers and conditions (Nicholson et al., 1994) . Single strand conformation-analysis of the amplification products was performed according to the procedure of Orita et al. (1989) . Band patterns of patients were compared with those of healthy controls. To determine the nature of the abnormal band observed for exon 3, the exon was reamplified from patient DNA. Subsequently, the amplified fragment was sequenced in both directions using the Cyclist sequencing kit (Stratagene, Westburg B.V., Leusden, The Netherlands) including 0.5 µl [ 32 P]dATP and either one of the amplification primers.
Statistical analysis
For statistical analysis the χ 2 test, Students t test and the Wilcoxon test were used (Department of Medical Statistics, University of Nijmegen).
Results

Molecular analysis
Using Southern blot analysis for gene-dosage measurements , the common 1.5-Mb deletion in chromosome 17p11.2 was shown to be present in the patients from 17 families. To determine whether a mutation in the PMP22 gene could cause the defect in the remaining six non-deletion families, linkage analysis with various highly polymorphic markers from the PMP22 gene region was performed in the largest family. The highest lod score was obtained with the marker D17S740 (Z max ϭ 2.62 at recombination fraction θ ϭ 0.0) which is in line with the genetic defect being in, or near, the gene for PMP22. The co-segregating haplotype was constructed for the six nondeletion families from the alleles of 10 microsatellite markers located in this area (see Patients and methods). Although genealogical studies of our families over three to four generations did not reveal a direct relationship, haplotype comparison revealed identity-by-descent arguing for a distant relationship with the same genetic defect inherited from a common ancestor.
To search for the actual molecular cause of the disorder, single strand conformation-analysis of the coding exons of the PMP22 gene was performed. An aberrant band pattern was detected only for exon 3. Sequencing of this exon revealed the presence of a heterozygous G-insertion in a stretch of six Gs (positions 276-281 of the open reading frame).
Clinical features
Clinical data of the 23 patients with the PMP22 G-insertion were compared with those of 63 patients with the 17p11.2 deletion (Table 1) . Age and gender distributions were similar in the G-insertion and deletion groups, allowing a statistical comparison of the two groups. The percentages of patients who had experienced transient deficits were not statistically different. However, the relative proportion of patients suffering from two or more transient palsies was significantly higher in the deletion group than in the G-insertion group. The deficit was sensory-motor or purely motor in 67% of the G-insertion group, compared with 73% of the deletion group. Painful palsies were not reported in either of the groups. It was not possible to obtain exact information about the number of transient deficits in several older patients, but at least 20 nerve palsy episodes were registered in the Ginsertion group and 52 episodes in the deletion group. Based on these data, it was shown that the peroneal nerves were those most often affected in both groups, but the relative number of peroneal nerve palsies was significantly higher in G-insertion patients (70%) than in the deletion patients (38%). Brachial plexus and ulnar nerve palsies were next in frequency (10% and 15%, respectively, in G-insertion patients and 25% and 21%, respectively, in deletion patients); median nerve and radial nerve palsies were the most infrequent in both groups (5% and 0%, respectively, in G-insertion patients and 11% and 4%, respectively, in deletion patients). Asymmetrical motor dysfunctions had persisted in 18% of the G-insertion patients and 11% of the deletion patients. Clinical examination revealed significantly more distal neuropathic symptoms and signs (marked pes cavus, total areflexia and symmetrical peroneal dysfunction) in the G-insertion group. In this group, all patients had clinical signs, whereas in the deletion group 15 subjects showed no abnormalities by clinical investigation and eight of these 15 had not experienced pressure palsies (12.6%). The mean age of these totally asymptomatic deletion carriers was 30 years (range 6-62 years), which is below the mean age of onset of our symptomatic deletion patients.
Electrophysiology
Both groups showed a general reduction of motor and sensory conduction and increased distal motor latencies in the upper and lower limbs (Table 2) . However, the motor nerve conduction in the ulnar and peroneal nerves and sensory conduction of the median nerves was significantly slower, and the distal motor latency in the peroneal nerves was significantly longer in the G-insertion group compared with the deletion group. Sensory conduction of the sural nerves was registered in 50 patients with the deletion, but in only six patients with the G-insertion. Statistical comparison of sural nerve registrations was not done as no response was obtained in five of the six G-insertion patients. There was a lower percentage of patients with a focal slowing of the motor nerve conduction over the elbow and fibula head in the patients with the G-insertion, but distal motor nerve conduction was slower in this group, and there was often no response at all.
Morphology
Seven patients (30%) in the G-insertion group and 20 patients (32%) in the deletion group underwent nerve biopsy (Table 2) .
Table 2 Electrophysiological features in G-insertion versus deletion patients
Normal values PMP22 G-insertion NS ϭ not significant; TTFA ϭ total transverse fascicular area. Onion bulb ratio ϭ number of onion bulbs per area of 100 myelinated fibres. Tomaculum frequency ϭ percentage of teased fibres with tomacula. Tomaculum diameter ϭ mean diameter of the 10 largest tomacula in two longitudinal sections. Morphometry data are given as mean Ϯ SD with range. *Values for age-matched control subjects are as follows. Mean densities of myelinated fibres (mm -2 ): 13180 (6-10 years, n ϭ 11); 10080 (11-30 years, n ϭ 12); 9760 (31-50 years, n ϭ 5); and 7890 (51-70 years, n ϭ 6). Percentage of fibres Ͼ 8 mm: 17 (6-10 years, n ϭ 11); 24 (11-30 years, n ϭ 12); 24 (31-50 years, n ϭ 5); and 27 (51-70 years, n ϭ 6). TTFA (mm 2 ): 0.72 (6-10 years, n ϭ 5); 0.87 (11-30 years, n ϭ 5); and 0.93 (31-70 years, n ϭ 5). † Values shown are percentages of those for normal age-matched control subjects.
Within both groups the patients who had a biopsy did not differ in age, or in clinical or electrophysiological parameters, from the non-biopsied patients (c 2 test, P ϭ 0.8-0.12). The percentages of teased fibres with tomacula in nerve biopsy were equal in both groups. Statistically significant differences were obtained for myelinated fibre density (G-insertion group Ͻ deletion group), percentage of large diameter fibres (Ginsertion group Ͻ deletion group), onion bulb ratio (Ginsertion group Ͼ deletion group) and tomaculum diameter (G-insertion group Ͻ deletion group) (Fig. 1) . The smaller tomaculum diameter in the G-insertion group is a logical consequence of smaller mean fibre diameter. The total transverse fascicular area was increased in the G-insertion group compared with the deletion group, but differences were not statistically significant.
Discussion
Eighty-six patients from 23 families fulfilled the criteria of HNPP: autosomal dominantly inherited liability to pressure palsies, electrophysiological evidence of a generalized polyneuropathy with focal slowing over pressure sites and tomacula in nerve biopsies. In 63 patients (17 families) the common 17p11.2 deletion was present, and in 23 patients (six families) we found a frame shift mutation in exon 3 of the PMP22 gene, giving rise to a distinct phenotype. Haplotype comparison revealed a distant relationship between these six families. As far as we could trace, at least four of the six families originated from 'Het Rivierenland', an area in The Netherlands shut in by the broad rivers Rhine and Waal, which have isolated the inhabitants of this area for a long time. This may explain the high number of affected but seemingly unrelated families occurring in a small geographical area. This founder effect also accounts for the high frequency of the non-deletion type in our HNPP families (Mariman et al., 1994) compared with others (Nelis et al., 1996) .
The clinical and electrophysiological features of our families with a deletion are essentially the same as those described in earlier reports (Gouider et al., 1995; Uncini et al., 1995; Amato et al., 1996; Cruz-Martinez et al., 1997) . Our population of deletion families includes two large families in which nearly all living members from three generations were examined both clinically and electrophysiologically (81 and 73 persons), which will diminish a positive selection of symptomatic patients occurring in small families. This might explain our slightly lower percentage of patients with pressure palsies (62%) compared with that reported in the literature (range 69-79%) (Amato et al., 1996; Cruz Martinez et al., 1997) , despite the higher mean age at examination in our group. On the other hand, the percentage of asymptomatic deletion carriers (12.7%) is the same as in earlier reports [Gouider et al., 1995 (11%) ; Uncini et al., 1995 (12.5%); Cruz-Martinez et al., 1997 (14%) ]. Gouider et al. (1995) reported nearly the same frequency of clinical abnormalities in their deletion patients (pes cavus 16.6%, ankle areflexia 58%, total areflexia 22%) as we found in our patients (Table 1 ). The range and topography of electrophysiological abnormalities, including conduction slowing over pressure sites, were also similar to those in earlier reports (Gouider et al., 1995; Uncini et al., 1995; Cruz Martinez et al., 1997) , although the percentage of abnormal registrations is slightly different due to a broader range in our normal values.
Our patients with the PMP22 G-insertion could undoubtedly be classified as suffering from HNPP as they did not differ qualitatively or quantitatively from the deletion patients with typical HNPP characteristics (pressure palsies, generalized slowing of nerve conduction velocities with predominant slowing over compression sites, prolonged distal latencies and tomacula in nerve biopsy). However, in addition they showed more severe pes cavus and areflexia, more symmetrical peroneal dysfunction, more marked conduction slowing and increased peroneal distal motor latencies, and in nerve biopsy clear signs of a mild demyelinating neuropathy with onion bulb formation and a conspicuous loss of large diameter fibres, resembling CMT1. In fact, some of our patients who had not suffered from recurrent palsies were initially diagnosed as having CMT1. Occasionally, individual patients with the common deletion may present with a generalized progressive sensorimotor neuropathy, resembling CMT1 (Gouider et al., 1995; Amato et al., 1996) . However, the electrophysiological features in these cases usually contrast with CMT1 by showing only mildly reduced conduction velocities (Kaku et al., 1993; Uncini et al., 1995) . In contrast, motor nerve conduction velocities in the patients of this study with the G-insertion were in the upper range of those reported for CMT1A. Although the percentage of patients with pressure palsies was equal in both groups, the patients with the G-insertion had experienced fewer episodes of palsy. This could be explained by differences in the mean age at examination (3.5 years less in the G-insertion patients than in the deletion group), and/or possibly also by a more cautious life style imposed by a more severe neuropathy.
The PMP22 gene is involved in alternative mutational mechanisms, causing different inherited peripheral neuropathies. It is currently postulated that an increased dosage of PMP22 through duplication of chromosome 17p11.2 is the cause of CMT1A; under-expression of PMP22 through the reciprocal deletion, resulting in a loss of function, is the major cause of HNPP (Lupski et al., 1991; Raeymaekers et al., 1991; Chance et al., 1993) . Single amino acid substitutions of PMP22 usually elicit a more severe CMT1A phenotype, often designated Dejerine-Sottas syndrome (Valentijn et al., 1992 Roa et al., 1993a, b) . While CMT1A with duplication results from PMP22 'overdose', it is suggested that a single amino acid substitution has a dominant negative effect (Suter and Snipes, 1995) . We have demonstrated that the two mutational mechanisms of the PMP22 gene giving rise to CMT1A (duplication and missense mutations) result in clearly different nerve pathology, favouring different pathogenic mechanisms (Gabreëls-Festen et al., 1995) . The morphological phenotype in missense mutations is characterized by a g-ratio (axonal diameter versus total fibre diameter) higher than normal (thin myelin sheaths) and the very early presence of large onion bulbs, which contrasts with the low g-ratio (relatively thick myelin sheaths) and the gradual formation of onion bulbs in duplication. Recently, a patient with severe CMT1A was described with a frame shift mutation in the PMP22 codon 94, resulting in a stop at codon 110 (Ionasescu et al., 1997) . Only few phenotypic details were given, and nerve pathology was not available.
Five different mutations in the PMP22 gene have resulted in an HNPP phenotype: three frame shift mutations, one nonsense mutation and one 5Ј splice site mutation. The mutation described by Nicholson et al. (1994) causes a frame shift and a premature stop at codon 36, rather like a functional deletion. The mutation described by Taroni et al. (1995) is predicted to cause a frame shift in codon 145 followed by a premature stop. Translation of the mutant allele will produce a polypeptide which is seven amino acids shorter than the wild type and lacks the normal C-terminal part of the protein.
The families with these two frame shift mutations had a similar phenotype to families with the common deletion. Pareyson et al. (1996) reported a nonsense mutation of codon 124 in a patient with typical HNPP also resulting in a shorter polypeptide at translation. Cruz-Martinez et al. (1997) found no significant differences between the patients of their family carrying a PMP22 78ϩ1(G→T) splicing mutation and patients carrying the deletion. This is the first detailed description of a different HNPP phenotype in a PMP22 frame shift mutation. The three patients of the family described by Young et al. (1997) with the same mutation as our patients showed early pes cavus and moderately reduced conduction velocities, also suggesting a more severe phenotype. The present mutation causes a frame shift at nt 276-281. The corresponding polypeptide has 221 amino acids with the first 94 amino acids similar to the wild type protein, followed by a changed sequence of 127 residues, which is 61 amino acids longer than the wild type and lacks the normal C-terminal part. The distinct phenotype in our Ginsertion patients, combining HNPP and a demyelinating neuropathy, indicates that a loss of PMP22 function occurs, similar to that in the common deletion. However, to explain the more severe phenotype, it is likely that translation of the mutated gene takes place, producing a large and markedly changed polypeptide, which apparently disturbs Schwann cell function, probably by hampering normal myelin formation or maintenance. The effect on Schwann cell function is milder than in cases of PMP22 missense mutations, and the morphology is markedly different, suggesting different pathogenic mechanisms.
